Selected published studies in adult aggressive B-cell lymphomas
| Trial . | No. . | Histology . | Median age, y (range) . | Stage (%) . | Regimen . | EFS . |
|---|---|---|---|---|---|---|
| Mead46 | 52 | Burkitt | 35 (15-60) | III-IV (61%) | CODOX-M/IVAC | 65% @ 2 y |
| Hoelzer47 | 363 | Burkitt | 42 (16-85) | III-IV (71%) | GMALL-B-ALL/NHL | 75% @ 5 y (PFS) |
| B-ALL | ||||||
| Ribrag48 | 260 | Burkitt | 39% < 40 y | III-IV (62%) | LMB vs | 62% |
| LMB-R | 75% | |||||
| Dunleavy49 | 30 | Burkitt | 33 (15-88) | III-IV (67%) | DA-EPOCH-R | 95% @ 7y (FFP) |
| SC-EPOCH-RR | 100% @ 6 y (FFP) | |||||
| Recher41 | 379 | DLBCL | 47 (18-60) | III-IV (55%) | R-CHOP | 73% @ 3 y (PFS) |
| R-ACVBP | 87% @ 3y (PFS) | |||||
| Cunningham38 | 1080 | DLBCL | 61 (18-88) | III-IV (62%) | R-CHOP-14 | 75% @ 2 y (PFS) |
| R-CHOP-21 | 75% @ 2 y (PFS) | |||||
| Wilson40 | 72 | DLBCL | 50 (19-85) | DA-EPOCH-R | 79% @ 5 y (PFS) | |
| Rieger55 | 87 | PMBCL | 36 (27-43) | All aa IPI 0-1 | R-CHOP | 78% @ 3 y |
| Dunleavy52 | 51 | PMBCL | 30 (19-52) | All stages | DA-EPOCH-R | 93% @ 5 y |
| Giulino-Roth54 | 156 | PMBCL | 31 (9-70) | All stages | DA-EPOCH-R | 86% @ 23 mo |
| Trial . | No. . | Histology . | Median age, y (range) . | Stage (%) . | Regimen . | EFS . |
|---|---|---|---|---|---|---|
| Mead46 | 52 | Burkitt | 35 (15-60) | III-IV (61%) | CODOX-M/IVAC | 65% @ 2 y |
| Hoelzer47 | 363 | Burkitt | 42 (16-85) | III-IV (71%) | GMALL-B-ALL/NHL | 75% @ 5 y (PFS) |
| B-ALL | ||||||
| Ribrag48 | 260 | Burkitt | 39% < 40 y | III-IV (62%) | LMB vs | 62% |
| LMB-R | 75% | |||||
| Dunleavy49 | 30 | Burkitt | 33 (15-88) | III-IV (67%) | DA-EPOCH-R | 95% @ 7y (FFP) |
| SC-EPOCH-RR | 100% @ 6 y (FFP) | |||||
| Recher41 | 379 | DLBCL | 47 (18-60) | III-IV (55%) | R-CHOP | 73% @ 3 y (PFS) |
| R-ACVBP | 87% @ 3y (PFS) | |||||
| Cunningham38 | 1080 | DLBCL | 61 (18-88) | III-IV (62%) | R-CHOP-14 | 75% @ 2 y (PFS) |
| R-CHOP-21 | 75% @ 2 y (PFS) | |||||
| Wilson40 | 72 | DLBCL | 50 (19-85) | DA-EPOCH-R | 79% @ 5 y (PFS) | |
| Rieger55 | 87 | PMBCL | 36 (27-43) | All aa IPI 0-1 | R-CHOP | 78% @ 3 y |
| Dunleavy52 | 51 | PMBCL | 30 (19-52) | All stages | DA-EPOCH-R | 93% @ 5 y |
| Giulino-Roth54 | 156 | PMBCL | 31 (9-70) | All stages | DA-EPOCH-R | 86% @ 23 mo |
GMALL, German acute lymphoblastic leukemia group.